Impact Biomedical Inc.
IBO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001834105
In the last 90 days, Impact Biomedical Inc. insiders filed 0 open-market purchases and 1 sale; 23 institutions reported holding it in 13F filings for Q2 2026, worth $1.76M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.69K in total
- 1
- 13F holdersQ2 2026, +3 vs. previous quarter
- 23
- 13F valueReported value at the end of Q2 2026
- $1.76M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IBO, Q2 2026
No superinvestor reported holding IBO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Impact Biomedical Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)7:37 PM ET | Sep 22-24 | 2 days | DSS, Inc.10% Owner | SSale | −906 | $1.86 | −$1.69K | −0.2%589.5K after | 3 lots |
| Mar 30, 2026 (view filing) | Mar 25-27 | 5 daysLate | Macko Todd DChief Financial Officer | SSale | −45.0K | $0.5614 | −$25.3K | −22.5%155.1K after | 2 lots |
| Mar 25, 2026 (view filing) | Mar 23 | 2 days | Grady JasonDirector | SSale | −50.0K | $0.65 | −$32.5K | −16.7%250.2K after | |
| Jan 6, 2026 (view filing) | May 22-27, 2025 | 229 daysLate | DSS, Inc.10% Owner | SSale | −161.0K | $0.5472 | −$88.1K | −22.8%545.0K after | 2 lots |
| May 27, 2025 (view filing) | May 22-27 | 5 days | DSS, Inc.10% Owner | SSale | −161.0K | $0.5472 | −$88.1K | −100.0%0 after | 2 lots |
| Apr 7, 2025 (view filing) | Apr 4 | 3 days | DSS, Inc.10% Owner | SSale | −890.8K | $0.95 | −$846.3K | −84.7%161.1K after | |
| Apr 7, 2025 (view filing) | Apr 3 | 4 days | Chan Heng Fai AmbroseDirector | SSale | −351.6K | $0.50 | −$175.8K | −100.0%0 after | |
| Apr 4, 2025 (view filing)5:15 PM ET | Apr 2-4 | 2 days | Chan Heng Fai Ambrose and 2 othersDirector, 10% Owner | SSale | −1.69M | $0.6646 | −$1.12M | −100.0%0 after | 7 lots |
| Apr 2, 2025 (view filing)9:01 PM ET | Mar 31-Apr 1 | 2 days | Chan Heng Fai Ambrose and 2 othersDirector, 10% Owner | SSale | −2.13M | $1.18 | −$2.52M | −74.3%734.1K after | 3 lots |
| Apr 2, 2025 (view filing)9:01 PM ET | Apr 1 | 1 day | Chan Heng Fai Ambrose and 2 othersDirector, 10% Owner | SSale | −400.0K | $0.982 | −$392.8K | −31.9%853.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Impact Biomedical Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 1,185,163 | $545.6K | 0.00% | −7,762−0.7% | Reduced |
| Vanguard Capital Management LLC | 808,689 | $372.0K | 0.00% | +100,521+14.2% | Added |
| State Street Corp | 607,897 | $279.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 589,428 | $271.1K | 0.00% | +4,230+0.7% | Added |
| BlackRock, Inc. | 259,946 | $119.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 235,475 | $108.3K | 0.00% | −8,468−3.5% | Reduced |
| Citadel Advisors LLC | 49,567 | $22.8K | 0.00% | +49,567 | New |
| Vanguard Global Advisers, LLC | 32,201 | $14.8K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 24,528 | $11.3K | 0.00% | +24,528 | New |
| Two Sigma Investments, LP | 17,191 | $7.91K | 0.00% | −20,236−54.1% | Reduced |